2,476 results match your criteria IDrugs[Journal]


Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs 2010 Dec;13(12):938-48

Boehringer Ingelheim (Canada) Ltd, Research and Development, 2100 Cunard Street, Laval, Québec, Canada H7S 2G5.

Filibuvir (PF-868554), being developed by Pfizer, is an orally administered, non-nucleoside inhibitor of the HCV NS5B RNA-dependent RNA polymerase for the potential treatment of chronic HCV infection. An estimated 180 million people worldwide are infected with HCV and at risk of developing chronic liver diseases that can lead to cirrhosis or hepatocellular carcinomas. HCV infection is the main cause of liver transplantation in industrialized nations. Read More

View Article
December 2010
7 Reads

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs 2010 Dec;13(12):929-37

University of Wisconsin-Madison, Department of Anesthesiology, School of Medicine and Public Health B6/319 Clinical Sciences Center, 600 Highland Avenue, Madison WI 53792-3272, USA.

Remimazolam (CNS-7056) is a short-acting GABA(A) receptor agonist, under development by PAION, in collaboration with Japanese licensee Ono Pharmaceutical, as an intravenous sedative agent for potential use in day-case procedures, and the induction and maintenance of anesthesia. A member of the benzodiazapene class of drugs, the structure of remimazolam was modified to produce a drug that displays organ-independent metabolism. The incorporation of a carboxylic ester moiety into the benzodiazapene core of remimazolam renders it susceptible to non-specific tissue esterases and it is rapidly metabolized into its pharmacologically inactive metabolite CNS-7054. Read More

View Article
December 2010
10 Reads

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs 2010 Dec;13(12):921-8

Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Charlton 8-110, 200 First St SW, Rochester, MN 55905, USA.

LX-1031, being developed by Lexicon Pharmaceuticals, is an oral, small-molecule tryptophan 5-hydroxylase (TPH) inhibitor that reduces 5-HT synthesis peripherally. LX-1031 is being developed for the potential treatment of diarrhea-predominant irritable bowel syndrome (IBS-D), which is characterized by excess 5-HT. In preclinical studies, LX-1031 dose-dependently reduced expression of 5-HT in the duodenum, jejunum and ileum, but had no effect on brain 5-HT levels. Read More

View Article
December 2010
63 Reads

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs 2010 Dec;13(12):911-20

Neuroscience Research Australia and Multi-disciplinary Amyotrophic Lateral Sclerosis Clinic, Prince of Wales Clinical School, University of New South Wales, Barker Street, Randwick, Sydney, NSW 2031, Australia.

Dexpramipexole (KNS-760704), the R(+) enantiomer of pramipexole, is under development by Knopp Neurosciences and Biogen Idec as a potential neuroprotective therapy for amyotrophic lateral sclerosis (ALS), a universally fatal neurodegenerative disease. Pramipexole, exclusively the S(-) enantiomer, is a non-ergot dopaminergic autoreceptor agonist that is currently marketed for use in the treatment of Parkinson's disease and restless legs syndrome. Pramipexole has been proposed to exert a broad spectrum of neuroprotective properties, primarily through antioxidant effects, inhibiting apoptotic enzymes and preserving mitochondrial structure and activity. Read More

View Article
December 2010
30 Reads

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

Authors:
Albert Adell

IDrugs 2010 Dec;13(12):900-10

Instituto de Investigaciones Biomédicas de Barcelona, Consejo Superior de Investigaciones Científicas, and Centro de Investigación Biomédica en Red de Salud Mental, Department of Neurochemistry and Neuropharmacology, Carrer Rosselló 161, Barcelona 08036, Spain.

Lu-AA21004, an oral, multimodal serotonergic agent, is currently under development by H Lundbeck and Takeda Pharmaceutical, for the potential treatment of depression and anxiety. Lu-AA21004 belongs to a novel chemical class of antidepressant agents, the bisarylsulfanyl amines, and possesses a novel pharmacological profile, with activity at serotonergic receptors 5-HT3, 5-HT7 and 5-HT1A, and also at the 5-HT transporter. Acute administration of Lu-AA21004 in rats inhibited the firing activity of serotonergic neurons of the dorsal raphe nucleus through 5-HT3 receptor blockade, with rapid recovery of firing activity upon cessation of treatment compared with an antidepressant of the SSRI class. Read More

View Article
December 2010
9 Reads

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs 2010 Dec;13(12):890-9

Tohoku University School of Medicine, Department of Pharmacology, 2-1, Seiryo-machi, Aoba-ku, Sendai 9808575, Japan.

Florbetapir (18F), being developed by Avid Radiopharmaceuticals, is an 18F-labeled PET tracer binding to amyloid-β (Aβ) plaques for the potential detection of Alzheimer's disease (AD). Preclinical studies indicated high binding affinity of florbetapir (18F) to Aβ fibrils and specific labeling of Aβ plaques in the cortical regions and hippocampus. In phase I and II clinical trials, florbetapir (18F) clearly differentiated patients with AD from healthy controls and uptake was most prominent in the precuneus. Read More

View Article
December 2010
19 Reads

Considerations in vaccine patent protection.

Authors:
Lorna Brazell

IDrugs 2010 Dec;13(12):885-9

Bird & Bird LLP, Intellectual Property Department, 15 Fetter Lane, London, EC4A 1JP, UK.

This feature article discusses the basic principles of patentability as related to vaccine research, and outlines recent cases in the US and EU in which vaccine patents have been considered. Issues regarding eligibility for supplementary protection, as currently being considered by the Court of Justice of the EU, are also outlined, as well as the implications of such issues in protecting future vaccine research. Read More

View Article
December 2010
8 Reads

Advances in flavivirus vaccine development.

IDrugs 2010 Dec;13(12):880-4

Hawaii Biotech Inc, 99-193 Aiea Heights Drive, Suite 200, Aiea, HI 96701, USA.

Flaviviruses comprise a diverse family of viruses that are cumulatively responsible for hundreds of millions of cases of infection annually. The Flavivirus genus includes both insect-vectored viruses, such as yellow fever and dengue, and non-vectored viruses such as HCV; the viruses have a broad range of disease presentation and geographic distribution. No specific antiviral therapies are currently available for the diseases caused by insect-vectored flaviviruses. Read More

View Article
December 2010
4 Reads

Improving lead generation success through integrated methods: transcending 'drug discovery by numbers'.

Authors:
James B Campbell

IDrugs 2010 Dec;13(12):874-9

AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, PO Box 15437, Wilmington, DE 19850-5437, USA.

Key methodologies such as HTS and combinatorial chemistry have allowed pharmaceutical discovery to focus on identifying promising drug candidates through the use of statistics. Thus, amassing large data sets from large-scale screening campaigns of ever-increasing corporate compound collections was expected to deliver unprecedented success for the pharmaceutical industry. This feature review explores aspects of how the reliance on using numbers to drive discovery has gone awry. Read More

View Article
December 2010
7 Reads

Lessons learned from candidate drug attrition.

IDrugs 2010 Dec;13(12):869-73

AstraZeneca Pharmaceuticals, 1800 Concord Pike, Wilmington, DE 19850, USA.

Rising expenditure in pharmaceutical R&D has not been matched by increased productivity. There is an urgent need to solve the current high levels of pipeline attrition. Changing the current failed model of drug discovery and development, in which high numbers of candidate drugs are produced and high attrition is accepted, is essential. Read More

View Article
December 2010
39 Reads

Accelerating the discovery of new drug targets with chemical proteomics.

IDrugs 2010 Dec;13(12):862-8

Novartis Institutes for BioMedical Research, Global Discovery Chemistry-Chemogenetics and Proteomics, 250 Massachusetts Aveune, Cambridge, MA 02139, USA.

The application of chemical proteomics to new target discovery can lead to a rapid understanding of disease mechanism and new therapeutic methods. Successful application includes a thorough understanding of SAR and the validation of target relevance using multiple genetic and biochemical methods. This feature review highlights several successful applications of chemical proteomics and outlines the strategy and approaches that lead to the discovery of novel therapeutic targets. Read More

View Article
December 2010
4 Reads

Strategies for conducting ADME studies during lead generation in the drug discovery process.

IDrugs 2010 Dec;13(12):857-61

Eli Lilly and Co, Lilly Corporate Center, Drop Code 0710, Indianapolis, IN 46285, USA.

Although the benefit of early ADME screening is widely recognized in the pharmaceutical industry, the implementation of this paradigm is often performed with insufficient resources and poor collaboration between functions. Dedicated and consistent integration efforts of ADME knowledge during the lead generation (LG) phase of drug discovery enables informed resourcing decisions and also increases the quality of initial starting points for discovery projects. To facilitate the efficient and consistent application of ADME resources to early projects at Eli Lilly and Co, a team of scientists was formed to provide dedicated ADME support to the LG phase of the discovery portfolio. Read More

View Article
December 2010
4 Reads

HIV vaccine development: past, present and future.

Authors:
Merlin L Robb

IDrugs 2010 Dec;13(12):852-6

US Military HIV Research Program, 1600 Gude Drive, Rockville, MD 20850, USA.

The search for an HIV vaccine began following the discovery of the virus more than 25 years ago. Despite important progress, an effective vaccine remains an elusive goal that will likely require many more years of R&D to achieve. Following recent advances in research, however, there has been increased optimism that a prophylactic HIV vaccine is feasible. Read More

View Article
December 2010
4 Reads

Nanocytology: a novel class of biomarkers for cancer management.

IDrugs 2010 Dec;13(12):847-51

Edeixa LLC, Marketing and Product Development, 28723 Colina Vista, Agoura Hills, CA 91301, USA.

Recently, cellular mechanical properties have received increasing attention as a potential biophysical marker for cancer cells. The analysis of mechanical profiles at the single-cell level may provide information that is potentially useful to assess tumor prognosis and response to therapy. This feature review discusses a novel nanocytology approach that combines traditional morphology assessment, molecular analysis and nanomechanical analysis of cancer cells. Read More

View Article
December 2010
4 Reads

MicroRNA dysregulation in cancer: opportunities for the development of microRNA-based drugs.

IDrugs 2010 Dec;13(12):843-6

Ohio State University, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, 473 West 12th Avenue, Columbus, Ohio 43210, USA.

MicroRNAs (miRNAs) are 19- to 24-nucleotide, non-coding RNAs that have been implicated in both solid and hematological malignancies. Given the ability of miRNAs to target multiple genes and key biological processes, these molecules have received intensive research interest both as biomarkers and as therapeutic agents. The prospect of leveraging miRNAs to complement current therapeutic strategies in cancer is appealing, but is also complex. Read More

View Article
December 2010
5 Reads

Biological Therapeutics Research and Development--GTCbio's Fifth Annual Conference. October 20-22, 2010, San Francisco, CA, USA.

Authors:
Hideki Garren

IDrugs 2010 Dec;13(12):840-2

Bayhill Therapeutics, 1804 Embarcadero Road, Suite 201, Palo Alto, CA 94303, USA.

The Biological Therapeutics Research and Development--GTCbio's Fifth Annual Conference, held in San Francisco, included topics covering new therapeutic developments in the field of vaccines and peptide therapies. This conference report highlights selected presentations on the development of vaccines for NSCLC, DNA delivery platforms as vaccines, vaccine combination therapy for cancer, DNA vaccines for autoimmune diseases, and improved peptide therapeutics. Investigational drugs discussed include TG-4010 (Transgene), and a series of vaccines targeting autoimmune diseases, including BHT-3021 (Bayhill/Genentech) for type I diabetes, BHT-3009 (Bayhill) for multiple sclerosis and BHT-3034 (Bayhill) for myasthenia gravis. Read More

View Article
December 2010
6 Reads

Mechanisms of Cell Death and Disease: Advances in Therapeutic Intervention and Drug Discovery--ESH's Eighth International Conference. October 14-17, 2010, Cascais, Portugal.

Authors:
Domagoj Vucic

IDrugs 2010 Dec;13(12):836-9

Genentech Inc, 1 DNA Way, M/S 40, South San Francisco, CA 94080, USA.

The Mechanisms of Cell Death and Disease: Advances in Therapeutic Intervention and Drug Discovery--ESH's Eighth International Conference, held in Cascais, Portugal, included topics covering new therapeutic developments in the field of cell death and cancer. This conference report highlights selected presentations on inhibiting the inhibitor of apoptosis (IAP) proteins, activating death receptors (DRs), and targeting ubiquitins and the Bcl-2 family. Investigational drugs discussed include LCL-161 (Novartis) and navitoclax (Abbott Laboratories/Genentech). Read More

View Article
December 2010
6 Reads

Targeted Cancer Therapies World Congress 2010--part 2. 21-23 September 2010, Zurich, Switzerland.

IDrugs 2010 Dec;13(12):833-5

ImClone Systems, Branchburg, 61 Imclone Drive, Branchburg, NJ 08853, USA.

The Targeted Cancer Therapies World Congress, held in Zurich, included topics covering new regulatory and therapeutic developments in the field of cancer therapy and accompanying diagnostics. This conference report highlights selected presentations on improving market access, minimizing redundant R&D investment and standardizing cancer biomarkers, incorporating diagnostics into drug development and advances in biomarker discovery for cancer. Read More

View Article
December 2010
5 Reads

Targeted Cancer Therapies World Congress 2010--part 1. 21-23 September 2010, Zurich, Switzerland.

IDrugs 2010 Dec;13(12):830-2

ImClone Systems, Branchburg, 61 Imclone Drive, Branchburg, NJ 08853, USA.

The Targeted Cancer Therapies World Congress, held in Zurich, included topics covering new developments in the field of cancer therapy. This conference report highlights selected presentations on the global market for targeted cancer therapies, understanding European regulatory evaluation strategies and meeting the requirements for acceptable reimbursement. Read More

View Article
December 2010
6 Reads

Alzheimer's Disease Drug Discovery--11th International Conference--Targeting Pathological Tau. 27-28 September 2010, Jersey City, NJ, USA.

Authors:
Michael S Wolfe

IDrugs 2010 Dec;13(12):828-9

Brigham & Women's Hospital and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.

The 11th Alzheimer's Disease Drug Discovery International Conference, held in Jersey City, NJ, USA, included topics covering new therapeutic developments in the field of Alzheimer's disease. This conference report highlights selected presentations on targeting pathological tau for the prevention or treatment of Alzheimer's disease. Investigational approaches discussed include aminothienopyridazine inhibitors of tau aggregation, the alternative splicing of tau pre-mRNA, protein phosphatase 2A as a potential therapeutic target, and immunotherapy and macroautophagy approaches for clearing aberrant tau protein from the brain. Read More

View Article
December 2010
7 Reads

Alzheimer's Disease Drug Discovery--11th International Conference--Promising New Therapeutic Approaches. 27-28 September 2010, Jersey City, NJ, USA.

Authors:
Michael S Wolfe

IDrugs 2010 Dec;13(12):825-7

Brigham & Women's Hospital and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.

The 11th Alzheimer's Disease Drug Discovery International Conference, held in Jersey City, NJ, USA, included topics covering new therapeutic developments in the field of Alzheimer's disease. This conference report highlights selected presentations on the use of patient-specific stem cells, and neuroprotection, regeneration and cognitive enhancement strategies for the prevention or treatment of Alzheimer's disease. Investigational approaches discussed include allopregnanolone for neuron protection and regeneration, PDE5 inhibitors as therapeutics, upregulating the protein Klotho to prevent cognitive decline, targeting memory deficits induced by Aβ42 oligomers, inhibiting striatal-enriched protein tyrosine phosphatase (STEP) for treating neuropsychiatric disorders, and agonism of GABA-A receptors to treat age-related cognitive deficits. Read More

View Article
December 2010
6 Reads

2010 World Stem Cell Summit--part 2. October 4-6, 2010, Detroit, MI, USA.

Authors:
Alain Vertès

IDrugs 2010 Dec;13(12):822-4

London Business School, Regent's Park, London, NW1 4SA, UK.

The 2010 World Stem Cell Summit, held in Detroit, included topics covering new developments in the field of regenerative medicine. This conference report highlights selected presentations on the cancer stem cell hypothesis, stem cell therapy for amyotrophic lateral sclerosis, GRNOPC-1 for spinal cord injury, the use of cord blood stem cells for spinal cord injury, mesenchymal stem cell research and applications in cardiac therapy, tissue engineering, and very small embryonic-like stem cells. Investigational drugs discussed include NSI-566RSC (Neuralstem) and GRNOPC-1 (Geron Corp). Read More

View Article
December 2010
6 Reads

2010 World Stem Cell Summit--part 1. October 4-6, 2010, Detroit, MI, USA.

Authors:
Alain Vertès

IDrugs 2010 Dec;13(12):819-21

London Business School, Regent's Park, London, NW1 4SA, UK.

The 2010 World Stem Cell Summit, held in Detroit, included topics covering new developments in the field of regenerative medicine. This conference report highlights selected presentations on government support for stem cell research in Michigan, financing stem cell development, regulatory and ethical considerations, Pharma's interest in allogeneic cell therapies, and the US Armed forces investment in regenerative medicine. Read More

View Article
December 2010
3 Reads

Targeted molecular therapy for preventing heart failure and sudden cardiac death. 28 September 2010, New York, NY, USA.

Authors:
Martin Schwarz

IDrugs 2010 Dec;13(12):816-8

Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA.

The targeted molecular therapy for preventing heart failure and sudden cardiac death discussion session, organized by the Biochemical Pharmacology Discussion Group of the New York Academy of Sciences and held in New York, included topics covering new research developments in the field of heart failure. This conference report highlights selected presentations on GPCRs for heart failure, calcium and heart function, and mitochondrial targets in heart failure. A summary of the panel discussion is also provided. Read More

View Article
December 2010
14 Reads

Partnerships in Pharma--An Economist Intelligence Unit Seminar--Building Innovation into Alliances and Business Models. 1 October 2010, London, UK.

Authors:
Alexandra Kibble

IDrugs 2010 Dec;13(12):813-5

Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK.

The Partnerships in Pharma seminar, held in London, included topics related to building innovation into alliances and business models within the pharmaceutical industry. This conference report highlights selected presentations on strategies for successful partnering, partnering alongside an evolving CRO industry, considering the pharma value chain, and partnerships between industry and academia. Approaches used by Ipsen, Merck Serono, Pfizer and ViiV Healthcare are also described. Read More

View Article
December 2010
8 Reads

Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus.

IDrugs 2010 Nov;13(11):793-801

University of Toledo, College of Medicine, Department of Orthopaedic Surgery, 3000 Arlington Avenue, Toledo, OH 43614, USA.

PPARγ and PPARα are nuclear receptors mainly involved in the regulation of glucose homeostasis and lipid levels, respectively. Aleglitazar, being developed by Roche Holding, is a dual agonist for PPARγ and PPARα for the potential simultaneous treatment of hyperglycemia and dyslipidemia in patients with type 2 diabetes mellitus (T2DM). In preclinical studies, aleglitazar decreased non-fasted glucose levels, increased glucose clearance and improved insulin resistance, while also increasing HDL-cholesterol and decreasing LDL-cholesterol levels in serum. Read More

View Article
November 2010
6 Reads

Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia.

IDrugs 2010 Nov;13(11):782-92

Detroit Medical Center Cardiovascular Institute, Clinical Cardiology, 3990 John R Street, Suite 9370, Detroit, MI 48201, USA.

Lixivaptan (VPA-985), being developed by Biogen Idec and Cardiokine, under license from Wyeth (now part of Pfizer), is a non-peptide, selective vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia associated with heart failure. Arginine vasopressin, the native V2 receptor ligand, stimulates water reabsorption via activation of V2 receptors that are expressed in the collecting ducts of the kidney. In preclinical studies, lixivaptan displayed competitive antagonist activity at V2 receptors in vitro, and increased urine volume and decreased urine osmolality in rats and dogs. Read More

View Article
November 2010
8 Reads

The clinical potential and challenges of sequencing cancer genomes for personalized medical genomics.

IDrugs 2010 Nov;13(11):778-81

The University of Queensland, Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, 306 Carmody Road, St Lucia, QLD 4072, Australia.

Next-generation sequencing is revolutionizing the way in which genomic-scale biological research is performed, and its effects are beginning to be translated medically. Large-scale international collaborations for the comprehensive sequencing of the genome, epigenome, and transcriptomes of cancers and corresponding 'normal' (germ-line) DNA are heralding the start of personalized medical genomics. The promise of eliminating conjecture when determining treatment approaches is certainly appealing for both patients and clinicians; however, several major issues must be resolved before next-generation sequencing will be adopted as a routine clinical tool for patients. Read More

View Article
November 2010
5 Reads

Using large-scale RNAi screens to identify novel drug targets for cancer.

IDrugs 2010 Nov;13(11):772-7

Netherlands Cancer Institute, Division of Molecular Carcinogenesis and NKI Robotics and Screening Center, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.

In recent years, the development and clinical implementation of targeted therapeutics have progressed significantly. The specific inhibition of components of signal transduction pathways controlling proliferation and survival has been a highly successful research strategy. However, cancer is a heterogeneous disease and, even within one type of cancer, different genetic alterations are associated with identical phenotypes. Read More

View Article
November 2010
4 Reads

Metastasis and the Tumor Microenvironment: A Joint Metastasis Research Society-AACR Conference - Research on Metastasis: part 2.

Authors:
Suzanne A Eccles

IDrugs 2010 Nov;13(11):768-71

Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, McElwain Labs, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.

The Metastasis and the Tumor Microenvironment Conference, held in Philadelphia, included topics covering new research developments in the field of metastasis and tumor microenvironment. This conference report highlights selected presentations on translation targets from a clinical perspective, antibody inhibitors of TGFβ for metastasis suppression, metastasis in bladder and lung cancer, c-ErbB2/HER2 expression in ductal carcinomas in situ and breast cancer, targeting Hsp90 chaperones in solid cancers, peritoneal carcinomas, and the discovery and exploitation of RANK ligands in bone metastasis. Investigational drugs discussed include the humanized antibody against TGFβ fresolimumab (GC-1008; Genzyme), the anti-VEGFR1 antibody icrucumab (IMC-18F1; ImClone Systems) and the novel Hsp90 inhibitor NVP-AUY-922 (AUY-922, VER-52296; Novartis). Read More

View Article
November 2010
5 Reads

Metastasis and the Tumor Microenvironment: A Joint Metastasis Research Society-AACR Conference - Research on Metastasis: Part 1.

Authors:
Suzanne A Eccles

IDrugs 2010 Nov;13(11):765-7

Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, McElwain Labs, 15 Cotswold Road, Sutton, Surrey, SM2 5NG.

The Metastasis and the Tumor Microenvironment Conference, held in Philadelphia, included topics covering new research developments in the field of metastasis and tumor microenvironment. This conference report highlights selected presentations on angiogenesis biomarkers, vessel stabilization, genetic determinants of site-specific metastasis and metastasis suppressor genes, including nm23 and KiSS1. Read More

View Article
November 2010
5 Reads

European Respiratory Society (ERS) - 20th Annual Congress.

Authors:
John Paul Seale

IDrugs 2010 Nov;13(11):762-4

University of Sydney, Broadway, Sydney, NSW 2006, Australia.

The European Respiratory Society Congress, held in Barcelona, included topics covering new therapeutic developments in the field of respiratory health and disease. This conference report highlights selected presentations on therapies targeting inflammatory cells, with a focus on therapeutic agents for asthma and COPD. This report also includes a discussion of novel therapeutic agents for pulmonary hypertension. Read More

View Article
November 2010
6 Reads

Gene Based Vaccines: Optimising Development and Delivery - A marcus evans Conference.

Authors:
Hideki Garren

IDrugs 2010 Nov;13(11):759-61

Bayhill Therapeutics Inc, 1804 Embarcadero Road, Suite 201, Palo Alto, CA 94303, USA.

The Gene Based Vaccines: Optimising Development and Delivery conference, held in Vienna, included topics covering new therapeutic developments in the field of gene-based vaccines. This conference report highlights selected presentations on gene-based vaccine delivery systems, anti-vector immunity in such vaccines, gene-based influenza vaccines, prime-boost strategies for influenza vaccines, DNA vaccines for the prevention of malaria, considerations in DNA vaccine manufacturing, and the ImmunoBody DNA vaccine technology from Scancell. Read More

View Article
November 2010
3 Reads

Japan Biotech Forum: London 2010.

Authors:
Asma Al-Shamahi

IDrugs 2010 Nov;13(11):756-8

Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK.

The Japan Biotech Forum, held in London, included topics covering new licensing developments in the Japanese pharma and biotech industries. This conference report highlights selected presentations on licensing opportunities from several Japanese companies, including CanBas, LivTech, REGiMMUNE, D Western Therapeutics Institute and Chiome Bioscience. Investigational drugs discussed include CBP-501 (CanBas), LIV-2008 (LivTech), RGI-2001 (REGiMMUNE), IVX-214 (D Western Therapeutics Institute/ Nippon Shinyaku) and anti-Sema 3A (Chiome Bioscience). Read More

View Article
November 2010
5 Reads

European College of Neuropsychopharmacology (ECNP) - 23rd Congress.

Authors:
David P Finn

IDrugs 2010 Nov;13(11):753-5

National University of Ireland Galway, Pharmacology and Therapeutics, School of Medicine, University Road, Galway, Ireland.

The 23rd Congress of the European College of Neuropsychopharmacology (ECNP), held in Amsterdam, included topics covering new therapeutic developments in the field of neuropsychopharmacology. This conference report highlights selected presentations on potential psychotropic drug targets, the relationship between psychiatric disorders and pain, treatments for depression and anxiety disorders, the role of glucocorticoid receptors in memory consolidation, and the use of anticonvulsants in impulse disorders. Read More

View Article
November 2010
2 Reads

Medicinal Chemistry - XXIst International Symposium.

Authors:
Danny Chan

IDrugs 2010 Nov;13(11):749-52

Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK.

The XXIst International Symposium on Medicinal Chemistry from the European Federation of Medicinal Chemistry (EFMC-ISMC), held in Brussels, included topics covering new therapeutic developments in the field of medicinal research. This conference report highlights selected presentations on therapies for neuropathic pain, cognitive disorders, cancer and infection. Investigational drugs discussed include the anticancer imidazole derivative IRC-083927 (Ipsen), the HCV protease inhibitor TMC-435 (Tibotec Pharmaceuticals) and the tuberculosis therapy bedaquiline (Tibotec Pharmaceuticals). Read More

View Article
November 2010
6 Reads

Interscience Conference on Antimicrobial Agents and Chemotherapy - 50th Annual Meeting - Research on Promising New Agents: Part 2.

Authors:
Karen Walker

IDrugs 2010 Nov;13(11):746-8

Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK.

The 50th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held in Boston, included topics covering new therapeutic developments in the field of infectious disease. This conference report highlights selected presentations on research with novel antimicrobial agents. Investigational drugs discussed include the chitin synthase inhibitor nikkomycin Z (Valley Fever Solutions/University of Arizona), the glycosylphosphatidylinositol biosynthesis inhibitor E-1210 (Eisai), the β-1,3-d-glucan synthesis inhibitor MK-3118 (Merck & Co/SCYNEXIS), the metalloenzyme inhibitors VT-1129 and VT-1161 (both Viamet Pharmaceuticals), and the anti-inflammatory nanoemulsion NB-003 (NanoBio). Read More

View Article
November 2010
4 Reads

Interscience Conference on Antimicrobial Agents and Chemotherapy - 50th Annual Meeting - Research on Promising New Agents: Part 1.

Authors:
Karen Walker

IDrugs 2010 Nov;13(11):743-5

Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK.

The 50th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held in Boston, included topics covering new therapeutic developments in the field of infectious disease. This conference report highlights selected presentations on research with novel antimicrobial agents. Investigational drugs discussed include the dicationic porphyrin derivative XF-73 (Destiny Pharma), the tetracycline analog TP-434 (Tetraphase Pharmaceuticals), an elongation factor Tu inhibitor (Novartis Institutes for BioMedical Research), the dihydrofolate reductase inhibitor Rx-101005 (Trius Therapeutics), SII RMab, a fully human mAb to rabies glycoprotein (Massachusetts Biologic Laboratories/Serum Institute of India), the oral lipopeptide CB-183315 (Cubist Pharmaceuticals) for the treatment of Clostridium difficile-associated diarrhea, the phosphatidylcholine-specific phospholipase C (PC-PLC) inhibitor LMV-601 (Lumavita), and DS-003 (International Partnership for Microbicides), a small-molecule Gp120 inhibitor. Read More

View Article
November 2010
23 Reads

Preladenant, a novel adenosine A(2A) receptor antagonist for the potential treatment of parkinsonism and other disorders.

Authors:
John D Salamone

IDrugs 2010 Oct;13(10):723-31

University of Connecticut, Behavioral Neuroscience Division, Department of Psychology, 406 Babbidge Road, Unit 1020, Storrs, CT 06269-1020, USA.

Adenosine A(2A) receptor antagonists exert antiparkinsonian effects in animal models and several drugs in this class are currently being assessed in clinical trials. Preladenant (SCH-420814) is an adenosine A(2A) receptor antagonist with a high affinity and very high selectivity for adenosine A(2A) receptors, which is being developed by Merck & Co Inc (following its acquisition of Schering-Plough Corp) for the potential treatment of Parkinson's disease. Preclinical studies in rodent and primate models of parkinsonism demonstrated that preladenant can reverse the motor impairments induced by dopamine depletion or antagonism. Read More

View Article
October 2010
8 Reads

Mirabegron, a β₃-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder.

IDrugs 2010 Oct;13(10):713-22

William Beaumont Hospital, Department of Urology, 3811 West 13 Mile Road, Royal Oak, MI 48073, USA.

Mirabegron (YM-178), currently in development by Astellas Pharma Inc, is an orally active β₃-adrenoceptor (AR) agonist for the potential symptomatic treatment of overactive bladder (OAB). Mirabegron demonstrates nanomolar EC50 values against the human β₃-AR in biochemical assays with potent selectivity over the β₁- and β₂-ARs. Originally developed as a treatment for diabetes, the development of mirabegron was later refocused to OAB. Read More

View Article
October 2010
6 Reads

DNA-based influenza vaccines: evaluating their potential to provide universal protection.

IDrugs 2010 Oct;13(10):707-12

Inovio Pharmaceuticals, 1787 Sentry Parkway West, Building 18, Suite 400, Blue Bell, PA 19422, USA.

The recent outbreaks of the H5N1 and H1N1 pandemic influenza have highlighted the importance of developing fast, effective therapeutic strategies to prevent and/or limit the spread of future influenza outbreaks. Although current vaccines against influenza are generally effective, several limitations, including those associated with the amount of available vaccine, the time to vaccine production and vaccine efficacy, may encumber a mass vaccination strategy and effective targeting against future outbreaks. This feature review discusses the prospects of SynCon-derived DNA vaccines against influenza; such vaccines are expected to be effective at targeting many currently circulating influenza virus strains, as well as potentially targeting strains that may be associated with future outbreaks. Read More

View Article
October 2010
5 Reads

Bacterial vectors and delivery systems in cancer therapy.

IDrugs 2010 Oct;13(10):701-6

Comenius University, Institute of Molecular Biomedicine, Faculty of Medicine, Sasinkova 4, 811 08, Bratislava, Slovakia.

Live bacterial vectors may be useful tools for the development of novel cancer therapies that can be added to the repertoire of existing drugs. Several bacterial strains effectively colonize solid tumors and act as antitumor therapeutics. The naturally occurring tumor-colonizing characteristics of bacterial species such as Salmonella sp, Clostridium sp and Escherichia coli can be further modified by genetic manipulations, making these bacterial systems excellent vehicles for the production and targeted delivery of therapeutic molecules into cancer cells. Read More

View Article
October 2010
6 Reads

Empowered Antibody Therapies - IBC conference.

Authors:
Jens Herold

IDrugs 2010 Oct;13(10):698-700

TRION Pharma, Frankfurter Ring 193a, 80807 Munich, Germany.

The Empowered Antibody Therapies conference, held in Burlingame, CA, USA, included topics covering new therapeutic developments in the field of multispecific antibodies. This conference report highlights selected presentations on DVD-Igs from Abbott Laboratories, ImmTACs from Immunocore, 'Dock-and-Lock' technology from Immunomedics, the bispecific BiTE antibody blinatumomab from Micromet, and Triomabs from TRION Pharma and Fresenius Biotech. Read More

View Article
October 2010
3 Reads

Ubiquitin Drug Discovery and Diagnostics Conference - targeting E3 ligases.

IDrugs 2010 Oct;13(10):695-7

Elan Pharmaceuticals, 800 Gateway Boulevard, South San Francisco, CA 94080-7021, USA.

The Ubiquitin Drug Discovery and Diagnostics Conference, held in Philadelphia, included topics covering the role of E3 ligases in disease. This conference report highlights selected presentations on E3-E2 ligase interactions, the SCF cyclin F ubiquitin ligase complex, and targeting HectH9 and KF-1 E3 ligases. Pharmaceutical research discussed includes E3 programs from Progenra and efforts to modulate the Parkin ligase at Elan Pharmaceuticals. Read More

View Article
October 2010
10 Reads

The Immunotherapeutics and Vaccine Summit - CHI's fifth annual meeting - novel vaccines: adjuvants and delivery systems: part 2.

Authors:
Susan D Jones

IDrugs 2010 Oct;13(10):692-4

BioProcess Technology Consultants, 12 Gill Street, Suite 5450, Woburn, MA 01801, USA.

The Fifth Annual Immunotherapeutics and Vaccine Summit (ImVacS), held in Boston, included topics covering new developments in the field of adjuvants and delivery systems for vaccines. This conference report highlights selected presentations on vaccines for infectious diseases, the use of adenovirus 5 (Ad5) for oral vaccination, modes of delivery for vaccines, and the strategy of DNA vaccination. Read More

View Article
October 2010
4 Reads

The Immunotherapeutics and Vaccine Summit - CHI's fifth annual meeting - novel vaccines: adjuvants and delivery systems: part 1.

Authors:
Susan Dana Jones

IDrugs 2010 Oct;13(10):689-91

BioProcess Technology Consultants, 12 Gill Street, Suite 5450, Woburn, MA 01801, USA.

The Fifth Annual Immunotherapeutics and Vaccine Summit (ImVacS), held in Boston, included topics covering new developments in the field of adjuvants and delivery systems for vaccines. This conference report highlights selected presentations on improving vaccine quality and persistence through adjuvants, the development of AS04-adjuvanted Cervarix, and research on new adjuvants. Adjuvants discussed include thymalfasin, nutritive immune-enhancing delivery system (NIDS), W805EC, MIMOPATH and ISCOMATRIX; the use of lasers as adjuvants is also highlighted. Read More

View Article
October 2010
5 Reads

Carbohydrate - 25th international symposium.

IDrugs 2010 Oct;13(10):686-8

University of Notre Dame, Department of Chemistry and Biochemistry, 251 Nieuwland Science Hall, Notre Dame, IN 46556-5670, USA.

The International Carbohydrate Symposium (ICS), held in Tokyo, included topics covering new developments in the field of glycoscience research. This conference report highlights selected presentations on glycoside hydrolase 1 (GH1) substrate specificity, antibody/lectin binding to oligosaccharides, probing the enzymatic properties of oligosaccharyltransferase, galactolipid biosynthesis, galactose disaccharide binding to a Pseudomonas lectin, O-linked N-acetylglucosamine (O-GlcNAc) modification of proteins, and NMR J-coupling correlations in saccharides. Read More

View Article
October 2010
5 Reads

American Academy of Dermatology - 2010 summer meeting.

IDrugs 2010 Oct;13(10):683-5

Mount Sinai School of Medicine, 5 East 98th Street, 5th Floor, New York, NY 10029, USA.

The 2010 Summer Meeting of the American Academy of Dermatology, held in Chicago, included topics covering new therapeutic developments in the field of dermatological diseases, including psoriasis. This conference report highlights selected presentations on the use of etanercept, adalimumab and briakinumab in the treatment of psoriasis. Read More

View Article
October 2010
12 Reads

Virus and Infections 2010 - BIT's first world congress.

Authors:
Olga Garkavenko

IDrugs 2010 Oct;13(10):680-2

Living Cell Technologies, Hunters Corner, Manukau 2155, PO Box 23 566, Auckland, New Zealand.

The World Congress of Virus and Infections, held in Busan, South Korea, included topics reviewing the field of zoonoses. This conference report highlights selected presentations on surveillance, epidemiology and measures for the control and prevention of zoonotic diseases. Topics discussed include human factors influencing zoonoses, the molecular epidemiology of Crimean-Congo hemorrhagic fever, the emerging Nipah virus, and the re-emergence of cowpox virus. Read More

View Article
October 2010
3 Reads

International Cannabinoid Research Society - 20th annual symposium.

Authors:
David P Finn

IDrugs 2010 Oct;13(10):677-9

National University of Ireland, Galway, School of Medicine, Pharmacology & Therapeutics, University Road, Galway, Ireland.

The 20th Annual International Cannabinoid Research Society (ICRS) symposium, held in Lund, Sweden, included topics covering new therapeutic developments in the field of cannabinoids. This conference report highlights selected presentations on drug design and discovery, Δ⁹-tetrahydrocannabivarin, inhaled dronabinol, the presence of cannabinoid receptor 2 in brain neurons, and the role of the endocannabinoid 2-arachidonoylglycerol in the brain. Read More

View Article
October 2010
5 Reads